COMPANY DESCRIPTION: JN-International Medical Corporation (JNI), a US-based private biopharmaceutical corporation, develops infectious disease vaccines and diagnostics. Founded in 1998 by Dr Jeeri R Reddy in rural Oakland, Nebraska, JNI expanded and moved to Omaha, Nebraska, in 2000.For more than a decade the name JNI has been synonymous with high-quality, innovative products, sound business strategy, and a passion for people around the world who receive our products. Emphasis on basic research combined with an applied focus on unequivocal medical needs was instrumental to success and growth. These priorities are the blueprint upon which JNI was built and will continue to grow. Offices and clinical trial centers are in Abidjan, Ivory Coast, with vaccine cold-chain facilities in Burkina Faso. JNI is third ranking global biopharmaceutical corporation producing Meningococcal meningitis vaccines. JNI partners with multiple non-profit global health organizations, NGOs, local governments and communities to address health issues related to infectious diseases that scourge underserved communities in Africa, South East Asia and Latin America.
PRODUCTS AND CURRENT STATUS: JNI is the 3rd Bio-Pharmaceutical Company to develop a Meningococcal meningitis serogroup A/C/Y/W-135 diphtheria toxoid conjugate vaccine (NmVac4-DT™) and the only company to hold Patent No. US 8129147B2 for the manufacture of the vaccine.At present, this vaccine has completed Phase-2 trial in 3 clinical centers in Maryland with FDA oversight. JNI plans to proceed with a Phase-3 trial in 32 centers in 2016. Other products in our pipe-line are vaccines for Genital Herpes, Stroke, Alzheimer’s, Huntington and Hepatitis C. In 2009, JN acquired vaccine manufacturing facilities in Omaha from Pfizer. The JN facility was designed for manufacture, research and development of vaccines in compliance with FDA cGMP and is capable of producing approximately10 million doses annually.
MARKET: Global Data has calculated that the global meningococcal vaccines market generated approximately $1.2 billion in sales in 2012. This market is expected to continue to expand in size over the next 10 years, with a Compound Annual Growth Rate (CAGR) of 5.4%, and sales are projected to reach $4.6 billion by 2022. In 2015, we are in the process of obtaining Export Authorization and Certification from FDA. In 2015-6, we will be in the International Market. For 2015, our vaccine distribution network has been established in the Middle East, Africa, South Asia, South East Asia and South America. In 2017 following the Phase 3 trial, after Biological License Application (BLA) approval by FDA, the vaccine can be marketed in North America, Europe and the UK. JNI can produce conjugate vaccine for all ages at a lower price. Our selling price can be as low as $50 per dose with 70% margin. NmVac4- DT is free of animal components. NmVac4-DT is Halal, suitable and affordable for millions of Muslims and the general population worldwide.
COMPETITION: Competitors in the market including Sanofi and Novartis did not fulfill the North American and European market demand and their presence in the developing countries market is limited due to high price of $150/dose. GSK has plain polysaccharide meningitis vaccine (which is being phased out). It is not effective for younger and older populations; it can neither induce immune memory nor herd immunity and cannot ensure sustained protection compared to JN’s NmVac4-DT or Sanofi’s Menactra and Novartis’s Menveo vaccines (World Health Organization). Serum Institute of India, Baxter and GSK produce Meningitis conjugate vaccines for either serogroup A or C. These vaccines do not prevent worldwide disease outbreaks caused by serogroups A, C, Y & W-135.